Login to Your Account



Merrimack CEO resigns in major restructuring

By Michael Fitzhugh
Staff Writer

Monday, October 3, 2016

Amid slower-than-anticipated sales of its second-line pancreatic cancer drug Onivyde, Merrimack Pharmaceuticals Inc. president and CEO Robert Mulroy resigned and the company moved to cut 22 percent of its work force.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription